Publications by authors named "Javier Cerda"
Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule.
Rev Chilena Infectol
February 2019
Article Synopsis
- The last case of poliovirus type 2 was reported in 1999, leading the WHO in 2012 to recommend withdrawing the type 2 component of the oral polio vaccine (OPV) and switching to a bivalent OPV by 2016, with prior introduction of inactivated polio vaccine (IPV) to ensure population protection.
- Production issues with the two global IPV manufacturers have led to a reduced supply, prompting health groups to recommend a new approach in Latin America where a fraction of the IPV dose (IPV-f) is given via intradermal injection instead of the full intramuscular dose (IPV-C).
- The decision was supported by pediatric health organizations and discussed by opinion leaders, aiming to
[Remarks on the possibility of the introduction of fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule].
Rev Chilena Infectol
August 2018
As last notified case of poliomyelitis due to wild poliovirus type 2 was 1999, in 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) of the World Health Organization (WHO) recommended the withdrawal of the type 2 component of oral polio vaccine (OPV) and the introduction of bivalent OPV (bOPV) in all countries by 2016. WHO recommended also that the withdrawal should be preceded by the introduction of at least one dose of inactivated poliovirus vaccine (IPV) in routine immunization schedules. The introduction of IPV prior to the change of the bOPV in 2016 to trivalent OPV (tOPV) was based on the concept of ensuring that a substantial proportion of the population would be protected against type 2 polio after the removal of the type 2 OPV.
View Article and Find Full Text PDFBackground: In US and European literature, Legionella pneumophila is reported as an important etiologic agent of severe community-acquired pneumonia (CAP), but in Chile this information is lacking. The aim of this study was to determine the incidence and identify predictors of severe CAP caused by L pneumophila in Santiago, Chile.
Methods: A multicenter, prospective clinical study lasting 18 months was conducted; it included all adult patients with severe CAP admitted to the ICUs of four hospitals in Santiago.